Lilly starts $6.5B Houston API plant with its own workforce pipeline

Eli Lilly broke ground Sept. 21 on a $6.5 billion active pharmaceutical ingredient plant in northeast Houston that it expects to staff with more than 600 permanent employees and build with about 4,000 construction workers. Rather than only recruit for that workforce, Lilly committed $12.5 million to San Jacinto College to create a pathway into advanced chemical synthesis manufacturing careers "with no prior experience required," according to the company's announcement.

The money is aimed at the plant floor. Lilly said the San Jacinto relationship will fund training pathways and expand the equipment and facility capacity needed to produce technicians, operators and maintenance professionals, with Lilly experts helping to develop curriculum and prepare instructors. A separate $2.5 million donation to the college's foundation will fund scholarships. San Jacinto has a campus in Generation Park, the master-planned development where the plant is going up, according to Community Impact Newspapers.

Lilly said it is already hiring in Houston. Among the permanent roles the company highlighted are engineers, scientists, operations staff and lab technicians. "This facility will run on the talent of this community, powered by our relationship with San Jacinto College," said Edgardo Hernandez, who runs Lilly's manufacturing operations.

Lilly will not be the only large drugmaker building in the park. Bristol Myers Squibb said in August that it would invest $2.3 billion in a 600,000-square-foot manufacturing campus in Generation Park, Bisnow reported. The developer, McCord, has spent years positioning the 4,300-acre park for biotech and life sciences manufacturing. It stepped up investment in related education and workforce training after losing Amgen's $550 million biomanufacturing project in 2021, according to Bisnow.

The construction window is tight. State filings show the plant spanning at least six buildings and roughly 808,359 square feet on a 236-acre campus, with construction expected to conclude in November 2027, the Houston Chronicle reported. The newspaper noted that the filings are subject to change and may not cover the full development. Bechtel's manufacturing and technology unit appears to be supporting the project, based on a Bechtel job posting cited by Construction Dive.

The Houston site is tied to Foundayo, the brand name for orforglipron, Lilly's oral GLP-1 weight-management drug. The FDA approved it on April 1. When Lilly announced the site in September 2025, the drug was still awaiting that decision. The company says Foundayo is under regulatory review in more than 40 countries, with a full global rollout targeted for 2027, and is being studied for type 2 diabetes and obstructive sleep apnea.

Foundayo is a small molecule rather than a peptide. Lilly's release says that means it is made with more established technologies and can be scaled more readily, which fits a chemical synthesis plant rather than a biologics line. The site will also produce oligonucleotides, a class of medicines designed to switch off production of specific disease-related proteins. The Houston Chronicle reported that Lilly has said the plant could make small-molecule medicines for oncology, immunology and neuroscience as well.

Lilly says the site will embed digital automation throughout and use machine learning, AI, digitally integrated systems and advanced analytics to drive production. The training Lilly is funding still centers on technicians, operators and maintenance staff. San Jacinto's chancellor, Brenda Hellyer, said the pathways would serve "students and incumbent workers," which suggests the program is also meant to retrain people already in the regional workforce, not only new entrants.

Houston is one of ten U.S. manufacturing sites Lilly has announced since 2020, part of what it calls a $50 billion push to reshore medicine production. It is the fifth of those sites built to produce APIs. The others are Richmond, Virginia; Huntsville, Alabama; and two locations in Lebanon, Indiana. Construction Dive has reported the Richmond project at $5 billion and the Huntsville plant at $6 billion. Four more sites, in North Carolina, Wisconsin and Pennsylvania, will make injectable medicines and devices, and one in Lebanon will make genetic medicines.

Texas is paying part of the bill. Gov. Greg Abbott said last year that Lilly would receive $146 million in tax incentives from the state's Jobs, Energy, Technology and Innovation program, plus a $5.5 million grant from the Texas Enterprise Fund, according to the Houston Chronicle. Abbott called the project "the largest active pharmaceutical ingredient project in Texas history."